Drug Abuse
Conditions
Brief summary
The aim of this study is examining the combination of two FDA approved drugs, Opipramol and baclofen, which may increase rehabilitation from psychoactive substances. Previous studies have indicated a connection of sigma-1 receptor to cocaine abuse and raised the possibility that these receptors as mediators of drug craving . However previous studies showed partial efficacy with no significant relapse in relapse rates. The same is true for the use of GABAb-1 receptor antagonist. Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent. Moreover, previous open and controlled trials indicated that the GABAb-1 antagonist baclofen partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine. Our studies in an animal model for addiction have shown a significant effect of the combine treatment of the indicated medications both in decreasing relapse and increase of -number of respondents.
Interventions
DRUGOpipramol
PO
DRUGBaclofen
PO
Sponsors
Ministry of Health, Israel
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age will be 60-18, both sexes, seeking treatment in order to stop the consumption of materials
Exclusion criteria
* Did not include trial addicts with co-morbidity, kidney, heart, metabolic, neurological and psychiatric disorders (psychosis, chronic depression).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decreased craving | 1 month | Lower withdrawal symptom will be measured by questionnaires |
Countries
Israel
Contacts
Primary ContactPaola Roska, MD
Backup ContactKeren Goldman, MsC
Outcome results
None listed